Search Results

73 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 51

    Examining the impact of very low nicotine content (VLNC) on cigarette use patterns – a review of current evidence and suggestions for further research

    SHERWOOD N.
    Neil Sherwood Consulting, Nyon, Switzerland
    A number of scientists and regulatory bodies have called for a reduction in the nicotine content of cigarettes to a minimally addictive level in the expectation that there will be a subsequent increase in the number of smokers who quit and a...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco...
  4. TSRC, Tob. Sci. Res. Conf., 2017, 71, abstr. 106

    A study to examine changes in exposure to cigarette smoke chemicals when a smoker switches to using a tobacco heating product. Part I: study design

    GALE N.(1); McEWAN M.(1); ELDRIDGE A.(1); CAMACHO O.M.(1); McAUGHEY J.(1); MURPHY J.(1); LIU C.(1); PROCTOR C.J.(1); FEARON I.M.(1); SHERWOOD N.(2); BOWEN E.(3); McDERMOTT S.(3); HOLMES E.(3)
    (1) British American Tobacco (Investments) Ltd, Southampton, UK; (2) Neil Sherwood Consulting, Commugny, Switzerland; (3) Covance, Leeds, UK
    A tobacco heating product (THP), glo™, which heats rather than combusts tobacco and produces significantly reduced machine yields of chemical toxicants compared to combustible cigarettes, was assessed in this study. Biomarker of exposure (BoE)...
  5. CORESTA Congress, Berlin, 2016, Smoke Science/Product Technology Groups, ST 23

    Pharmacokinetics of nicotine following single controlled use of a new type of tobacco: heated tobacco product

    GILES L.(1); YUKI D.(2); SHERWOOD N.(3); GRAFF D.W.(4); NEWLAND K.(4)
    (1) JT International SA, Ballymena, Co. Antrim, U.K.; (2) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (3) Neil Sherwood Consulting, Commugny, Switzerland; (4) Celerion, Lincoln, NE, U.S.A.
    Nicotine is one of the most characteristic compounds contained in any type of tobacco product including cigarettes. Previous studies have reported that different types of tobacco products display differences in nicotine pharmacokinetics. NHTP is a...